Breaking News Instant updates and real-time market news.

BIIB

Biogen

$384.00

11.2 (3.00%)

16:29
07/25/18
07/25
16:29
07/25/18
16:29

Biogen says highest dose of BAN2401 showed slowing of clinical decline of 30%

Eisai and Biogen announced detailed results from the Phase 2 study with BAN2401, an anti-amyloid beta protofibril antibody, in 856 patients with early Alzheimer's disease as part of Session DT-01 "Recent Developments in Therapeutics" at the Alzheimer's Association International Conference being held in Chicago, Illinois. Through Bayesian interim analyses, the highest doses of 10 mg/kg monthly and 10 mg/kg biweekly were determined to be the treatment dosages with higher efficacy early in the trial, and as a result, the proportion of patients allocated to these treatment arms was greater. Following a regulatory request, outside of the United States, in July 2014, the allocation of APOE4 carriers to the 10 mg/kg biweekly treatment arm was restricted, resulting in fewer APOE4 carriers in this arm and more patients being allocated to the 10 mg/kg monthly treatment arm. BAN2401 demonstrated a dose-dependent reduction in amyloid plaques as measured by amyloid PET, and this reduction was statistically significant at all doses. At the highest dose of BAN2401 of 10 mg/kg biweekly, an analysis of amyloid accumulated in the brain using standardized PET as measured on the Centiloid scale showed an observed mean at baseline of 74.5 and at 18 months of 5.5. Using a Mixed-effects Model with Repeated Measures, the mean reduction in amyloid load was 70 units, which was statistically significant. In amyloid PET image visual read, BAN2401 demonstrated a dose dependent conversion from amyloid positive to negative, and at the highest dose, 81% of patients converted from amyloid positive to negative at 18 months. Conventional statistical methods on predefined clinical endpoints at the 18 month final efficacy time point confirmed a dose-dependent slowing in cognitive decline from baseline on ADCOMS. The highest treatment dose of 10 mg/kg biweekly demonstrated a statistically significant slowing of clinical decline of 30% compared to placebo at 18 months. A statistically significant slowing of decline on ADCOMS was observed as early as 6 months as well as at 12 months. Dose-dependent slowing in cognitive decline from baseline on ADAS-Cog was also observed for BAN2401, with the highest treatment dose of BAN2401 demonstrating a significant slowing of clinical decline compared to placebo at 18 months. Furthermore, dose-dependent slowing in cognitive decline from baseline on CDR-SB was observed, surpassing the pre-specified difference of 25% over the duration of the study. At 18 months, slowing of clinical decline for the highest treatment dose of BAN2401 compared to placebo on CDR-SB was 26%. The rate of clinical decline for the placebo group was consistent with the results of research by the Alzheimer's Disease Neuroimaging Initiative in the United States.

  • 25

    Jul

  • 25

    Jul

  • 30

    Jul

  • 31

    Jul

BIIB Biogen
$384.00

11.2 (3.00%)

07/24/18
PIPR
07/24/18
NO CHANGE
Target $400
PIPR
Overweight
Piper raises Biogen target to $400 after BAN2401 'stole the show' from earnings
Piper Jaffray analyst Christopher Raymond raised his price target on Biogen to $400 from $365 after "solid" Q2 results that he said were overshadowed by what "investors are interpreting as highly encouraging commentary" regarding the BAN2401 data that will be presented at tomorrow's AAIC meeting. Given what he sees as the "massive stock re-rating potential" associated with a viable Alzheimer's treatment, he thinks investors should continue to own the stock into tomorrow's BAN2401 data and ahead of full Phase 3 data for aducanumab in 2020. Raymond keeps an Overweight rating on Biogen shares.
07/24/18
JPMS
07/24/18
NO CHANGE
Target $445
JPMS
Overweight
JPMorgan expects 'FOMO' trading for Biogen, ups price target to $445
JPMorgan analyst Cory Kasimov said Biogen's "nice beat-and-raise" report was "an encouraging start" to the Q2 earnings season, adding that its MS franchise remains largely stable. Much of the conference call Q&A focused on Alzheimer's ahead of tomorrow's BAN2401 data presentation and he thought the overall tone of the conversation was "constructive," he tells investors. The analyst, who thinks a significant "fear of missing out" trade may take hold as the highly anticipated aducanumab data readout in early 2020 approaches, raised his price target on Biogen to $445 from $400 and keeps an Overweight rating on the shares.
07/25/18
ADAM
07/25/18
NO CHANGE
Target $396
ADAM
Buy
Biogen risk/reward positive into Alzheimer's conference, says Canaccord
Canaccord analyst Sumant Kulkarni noted Biogen reported better than expected Q2 results, which were driven by robust Spinraza sales, higher gross margins, and lower R&D expenses. The analyst said the focus is now on the company's BAN2401 presentation at the Alzheimer conference. He said he likes the risk/reward heading into this event. Kulkarni reiterated his Buy rating and $396 price target on Biogen shares.
07/25/18
RHCO
07/25/18
NO CHANGE
Target $392
RHCO
Buy
Biogen price target raised to $392 from $321 at SunTrust
SunTrust analyst Yatin Suneja raised his price target on Biogen to $392 and kept his Buy rating after its Q2 results, saying all key business segments contributed to a top-line beat, while lower cost of goods sold and R&D expenses drove the better than expected earnings. The analyst notes that investors are now focusing on the upcoming release regarding BAN2401 Alzheimer's data, estimating a 20% cognition improvement. Suneja also increased his FY19 expected EPS multiple to 14-times from 12-times as part of his price target revision.

TODAY'S FREE FLY STORIES

15:00
07/16/19
07/16
15:00
07/16/19
15:00
General news
Fed's Evans said a little more accommodation would be helpful »

Fed's Evans said a…

ESV

Ensco Rowan

$8.24

-0.21 (-2.49%)

14:55
07/16/19
07/16
14:55
07/16/19
14:55
Options
Ensco put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 27

    Aug

FB

Facebook

$203.23

-0.7 (-0.34%)

14:49
07/16/19
07/16
14:49
07/16/19
14:49
Hot Stocks
Facebook's Perault says Instagram, WhatsApp takeovers have benefited users »

In prepared remarks ahead…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 17

    Jul

  • 17

    Jul

  • 24

    Jul

UAL

United Continental

$94.14

2.84 (3.11%)

14:49
07/16/19
07/16
14:49
07/16/19
14:49
Options
United Continental options imply 6.7% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

MNST

Monster Beverage

$65.31

0.03 (0.05%)

, PM

Philip Morris

$81.31

-0.13 (-0.16%)

14:44
07/16/19
07/16
14:44
07/16/19
14:44
Recommendations
Monster Beverage, Philip Morris, British American Tobacco, Altria Group, Nielsen analyst commentary at Wells Fargo »

Wells says Nielsen…

MNST

Monster Beverage

$65.31

0.03 (0.05%)

PM

Philip Morris

$81.31

-0.13 (-0.16%)

BTI

British American Tobacco

$36.42

-0.23 (-0.63%)

MO

Altria Group

$49.20

-0.36 (-0.73%)

NLSN

Nielsen

$23.36

-0.05 (-0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 30

    Jul

CHFC

Chemical Financial

$40.69

-0.11 (-0.27%)

, TCF

TCF Financial

$20.63

-0.03 (-0.15%)

14:38
07/16/19
07/16
14:38
07/16/19
14:38
Hot Stocks
Federal Reserve approves Chemical Financial deal to acquire TCF Financial »

The Federal Reserve Board…

CHFC

Chemical Financial

$40.69

-0.11 (-0.27%)

TCF

TCF Financial

$20.63

-0.03 (-0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 25

    Jul

  • 23

    Sep

14:32
07/16/19
07/16
14:32
07/16/19
14:32
Conference/Events
Morgan Stanley India phama analyst to hold an analyst/industry conference call »

India Pharmaceuticals…

F

Ford

$10.43

0.015 (0.14%)

, GM

General Motors

$39.21

-0.15 (-0.38%)

14:25
07/16/19
07/16
14:25
07/16/19
14:25
Periodicals
U.S. car makers open UAW contract talks as labor costs rise, WSJ reports »

Major U.S. car makers are…

F

Ford

$10.43

0.015 (0.14%)

GM

General Motors

$39.21

-0.15 (-0.38%)

FCAU

Fiat Chrysler

$13.61

-0.565 (-3.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 31

    Jul

  • 01

    Aug

  • 12

    Aug

  • 23

    Oct

JBLU

JetBlue

$19.53

0.8 (4.27%)

14:25
07/16/19
07/16
14:25
07/16/19
14:25
Options
JetBlue call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

GOOG

Alphabet

$1,152.76

2.37 (0.21%)

14:25
07/16/19
07/16
14:25
07/16/19
14:25
Conference/Events
Senate Judiciary Committee to hold a hearing »

The Subcommittee on the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 17

    Jul

  • 25

    Jul

  • 08

    Aug

  • 27

    Oct

14:25
07/16/19
07/16
14:25
07/16/19
14:25
Conference/Events
JPMorgan SMid Cap biotech analyst to hold an analyst/industry conference call »

SMid Biotech Analyst Fye,…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
07/16/19
07/16
14:17
07/16/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
07/16/19
07/16
14:16
07/16/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CFRX

ContraFect

$0.47

-0.0187 (-3.83%)

14:12
07/16/19
07/16
14:12
07/16/19
14:12
Conference/Events
ContraFect management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

14:10
07/16/19
07/16
14:10
07/16/19
14:10
General news
More from Kaplan: he thinks the funds rate will stabilize after just one rate cut »

More from Kaplan: he…

ATEC

Alphatec

$4.38

-0.06 (-1.35%)

14:09
07/16/19
07/16
14:09
07/16/19
14:09
Syndicate
Breaking Syndicate news story on Alphatec »

Alphatec files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 12

    Sep

SPOT

Spotify

$154.15

-0.13 (-0.08%)

, AAPL

Apple

$203.82

-1.36 (-0.66%)

14:08
07/16/19
07/16
14:08
07/16/19
14:08
Hot Stocks
Spotify slides after Apple said to plan original, exclusive podcasts »

Spotify (SPOT) shares are…

SPOT

Spotify

$154.15

-0.13 (-0.08%)

AAPL

Apple

$203.82

-1.36 (-0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 31

    Jul

MCD

McDonald's

$213.70

-0.48 (-0.22%)

, UBER

Uber

$44.37

-0.14 (-0.31%)

14:04
07/16/19
07/16
14:04
07/16/19
14:04
Hot Stocks
McDonald's adds DoorDash as U.S. delivery partner »

McDonald's USA and…

MCD

McDonald's

$213.70

-0.48 (-0.22%)

UBER

Uber

$44.37

-0.14 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 08

    Aug

APRN

Blue Apron

$12.46

4.81 (62.88%)

14:00
07/16/19
07/16
14:00
07/16/19
14:00
Options
Explosive action in BlueApron as partnership with BYND anhiliates shorts »

Explosive action in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

AAPL

Apple

$204.13

-1.05 (-0.51%)

, SPOT

Spotify

$154.63

0.35 (0.23%)

13:59
07/16/19
07/16
13:59
07/16/19
13:59
Periodicals
Apple to fund original podcasts in challenge to Spotify, Bloomberg says »

Apple (AAPL) plans to…

AAPL

Apple

$204.13

-1.05 (-0.51%)

SPOT

Spotify

$154.63

0.35 (0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 31

    Jul

TSLA

Tesla

$252.11

-1.3 (-0.51%)

13:55
07/16/19
07/16
13:55
07/16/19
13:55
Hot Stocks
Tesla CEO Musk says cost of FSD option will increase 'every few months' »

Tesla CEO Elon Musk said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 06

    Aug

CARS

Cars.com

$20.95

-0.56 (-2.60%)

13:55
07/16/19
07/16
13:55
07/16/19
13:55
Options
Cars.com put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$28.93

-0.29 (-0.99%)

, ABT

Abbott

$83.27

-0.53 (-0.63%)

13:50
07/16/19
07/16
13:50
07/16/19
13:50
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

BAC

Bank of America

$28.93

-0.29 (-0.99%)

ABT

Abbott

$83.27

-0.53 (-0.63%)

USB

U.S. Bancorp

$53.04

-0.07 (-0.13%)

PNC

PNC Financial

$138.85

-1.33 (-0.95%)

PGR

Progressive

$84.25

0.245 (0.29%)

BK

BNY Mellon

$43.20

0.05 (0.12%)

OMC

Omnicom

$84.47

0.46 (0.55%)

TXT

Textron

$54.17

0.74 (1.39%)

CMA

Comerica

$71.70

0.34 (0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 26

    Aug

  • 06

    Sep

  • 16

    Oct

CSX

CSX

$79.79

1.27 (1.62%)

, CTAS

Cintas

$243.78

0.47 (0.19%)

13:49
07/16/19
07/16
13:49
07/16/19
13:49
Earnings
Notable companies reporting after market close »

Notable companies…

CSX

CSX

$79.79

1.27 (1.62%)

CTAS

Cintas

$243.78

0.47 (0.19%)

UAL

United Continental

$94.36

3.06 (3.35%)

FNF

Fidelity National

$41.43

-0.12 (-0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 16

    Jul

  • 17

    Jul

  • 17

    Jul

  • 01

    Aug

  • 26

    Aug

  • 13

    Nov

GLYC

GlycoMimetics

$12.62

-0.17 (-1.33%)

13:45
07/16/19
07/16
13:45
07/16/19
13:45
Options
GlycoMimetics call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 09

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.